Denosumab versus zoledronic acid for skeletal-related events in breast cancer patients with bone metastases

Share :
Published: 28 Jan 2010
Views: 9195
Rating:
Save
Dr Alison Stopeck - University of Arizona Cancer Center
Among patients with bone metastasis from breast cancer, denosumab was superior to zoledronic acid in reducing the incidence of complications from bone metastases. Denosumab prevented more events, was better tolerated and is more convenient for patients. Official San Antonio Breast Cancer Symposium press conference.